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Background: Prenatal exposures may contribute to male infertility in adult life, but large-
scale epidemiological evidence is still lacking. The Fetal Programming of Semen quality
(FEPOS) cohort was founded to provide means to examine if fetal exposures can interfere
with fetal reproductive development and ultimately lead to reduced semen quality and
reproductive hormone imbalances in young adult men.
Methods: Young adult men at least 18 years and 9 months of age born to women in the
Danish National Birth Cohort living in relative proximity to Copenhagen or Aarhus and for
whom a maternal blood sample and two maternal interviews during pregnancy were avail-
able were invited to FEPOS. Recruitment began in March 2017 and ended in December
2019. The participants answered a comprehensive questionnaire and underwent a physical
examination where they delivered a semen, urine, and hair sample, measured their own
testicular volume, and had blood drawn.
Results: In total 21,623 sons fulfilled eligibility criteria of whom 5697 were invited and
1058 participated making the response rate 19%. Semen characteristics did not differ
between sons from the Copenhagen and Aarhus clinics. When comparing the FEPOS
semen parameters to similar cohorts, the median across all semen characteristics was slightly
lower for FEPOS participants, although with smaller variation.
Conclusion: With its 1058 young adult men, the FEPOS cohort is the largest population-based
male-offspring cohort worldwide specifically designed to investigate prenatal determinants of
semen quality. Wide-ranging information on maternal health, lifestyle, socioeconomic status,
occupation, and serum concentrations of potential reproductive toxicants during pregnancy
combined with biological markers of fertility in their sons collected after puberty allow for in-
depth investigations of the ‘fetal origins of adult disease hypothesis’.
Keywords: male infertility, prenatal exposure, fetal exposure, maternal-fetal exchange,
semen quality, semen analysis
Introduction
Infertility is the most common chronic disease among people of reproductive age,
and affects up to 15–25% of all couples trying to achieve a pregnancy.1–3 Male
factor infertility is a contributing factor in up to half of these cases.4 Around 40% of
Danish men have a semen concentration below 40 million/mL, from where the
probability for conception gradually decreases.5 Several factors in adult life have
been linked to reduced semen quality, including lifestyle such as smoking, chronic
alcohol use, obesity, sleep, and nutrition6–12 and occupational and environmental
exposures such as sedentary work, radiation, air pollution, bisphenol A, parabens,
organophosphate pesticides, pyrethroids, and phthalates.13–17 Still, subfertility
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remains unexplained for many, and the underlying causes
are far from understood. According to the ‘fetal origins of
adult disease hypothesis’ suggested by Barker and
Osmond in 1986, the environment encountered during
fetal life is strongly related to the risk of developing
non-communicable diseases later in life.18 This was sup-
ported by Sharpe and Skakkebæk,19 who subsequently
proposed that hypospadias, cryptorchidism, poor semen
quality, and testicular cancer are symptoms of one under-
lying entity with a common fetal origin.20,21 Although an
increasing number of studies of maternal lifestyle and
health during pregnancy, such as maternal diet, alcohol
consumption, smoking, medication use, and obesity sup-
port this fetal programming hypothesis,22–27 large-scale
epidemiological evidence is still lacking – especially
regarding maternal exposure to endocrine disrupting che-
micals at home and at work.28 The limited body of evi-
dence is likely explained by the complex logistics and high
costs of establishing long-term longitudinal population-
based studies of male reproductive function, with informa-
tion on exposures during early life, such as the need for
detailed maternal information and bio-specimens stored
for decades before follow-up.
The Fetal Programming of Semen quality (FEPOS)
cohort is nested within the Danish National Birth Cohort
(DNBC)29,30 and was founded to provide means to exam-
ine if fetal exposures can interfere with fetal reproductive
development and ultimately lead to reduced semen quality
and reproductive hormone imbalances in young adult men.
Methods
Study Population
In March 2017, FEPOS was established as a male-off-
spring sub-cohort within the DNBC. In total, 49,653 sons
were born into the DNBC cohort. A full flow chart of the
sampling strategy is depicted in Figure 1. Sons eligible to
participate in FEPOS should still be enrolled in the DNBC
(N=46,911) with mothers having participated in the two
maternal computer-assisted telephone interviews con-
ducted around gestational week 16 and 31 (N=41,518)
and with a stored gestational blood sample in the DNBC
biobank (N=39,725).30 Further, the FEPOS participants
had to be at least 18 years and 9 months of age within
the study period (N=24,024) (this arbitrary age cut off was
due to an 18-year follow-up in the original DNBC cohort),
not dead or emigrated (N=23,425) and live in Zealand
(N=8817) or Jutland (N=12,806) in relative proximity to
the FEPOS clinics in Copenhagen or Aarhus. Thus, the
total number of young men eligible for invitation was
21,623.
The Aarhus clinic included participants until June 2018
where it was closed due to a lack of funding. The
Copenhagen clinic included participants in the entire
study period that ended in December 2019. In total, 5697
men were invited and 1058 participated making the
response rate 19%.
Recruitment Logistics
Using a digitalized and comprehensive recruitment sys-
tem, eligible sons were randomly selected for invitation
to participate on an ongoing basis during the study period
(Figure 2). The monthly number of sons invited varied in
the two clinics according to capacity. An invitation letter
was sent to the young men’s personal and secure digital
mailbox “e-Boks” linked to the unique personal identifica-
tion number. E-Boks is automatically created at the age of
15 years and used for bi-directional communication with
public and private authorities, eg to receive pay checks or
bank statements.31 The invitation letter included informa-
tion about the study and an electronic option to be con-
tacted for additional information or decline participation.
The invitation letter specified that participants who had
undergone sterilization, cancer treatment, orchidectomy, or
had one or no testicles were ineligible. Of the 5697 invited
sons 1880 requested more information and were contacted
by telephone by a member of the project group. Those still
wishing to participate after the verbal information was
given (N=1453), received an electronic informed consent
form by e-Boks. Upon digitally consenting using their
common secure login “NemID” (N=1248), participants
received links to an online questionnaire and booking
system to schedule an appointment for a clinical examina-
tion at the clinic closest to their home (Figure 3). After
answering the online questionnaire (N=1174) participants
underwent a clinical examination (N=1058). At each step
of contact, non-responders were sent two reminders by
e-Boks, with 14 days interval, and at the initial invitation
a final reminder was sent by regular mail. Participants
were each remunerated 500 DKK (≈ 67 Euro).
Data and Measurements
An overview of data collected from the questionnaire and
clinical examination data is presented in Table 1.
Keglberg Hærvig et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Clinical Epidemiology 2020:12758
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
18
8.
17
7.
26
.5
 o
n 
01
-A
ug
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Questionnaire Information
Participants filled out a comprehensive web-based question-
naire administered electronically using SurveyXact. The ques-
tionnaire included questions regarding education, work,
health, and health behavior (Table 1). Nationally validated
questionnaire scales were used where possible.32–35 To ensure
that questions were explicit and easily understood by this age
group, the questionnaire was tested and revised in a group of
nine young men before being sent to the FEPOS participants.
Clinical Examination
The clinical examination was performed by a trained bio-
medical laboratory technician at either the Department of
Occupational and Environmental Medicine at Bispebjerg
and Frederiksberg Hospital (Copenhagen) or the
Department of Occupational Medicine at Aarhus
University Hospital (Aarhus).
Height and waist circumference in centimeters were
measured using a seca® 213 Height Measure and seca®
201 measuring tape, respectively (seca®, Hamburg,
Germany). Body weight in kilos, fat percentage (including
visceral fat), fat mass, fat-free mass, water percentage,
muscle mass, basal metabolic rate, metabolic age, and
bone weight were measured using a MC-780MA Body
Composition Analyzer (Tanita®, Tokyo, Japan). Blood
pressure was measured three times with 2–3 min interval
Figure 1 Flowchart of the sampling strategy and recruitment process of the FEPOS cohort.
Dovepress Keglberg Hærvig et al
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on the right arm, with a BP A3 Plus monitor (Microlife®,
Taipei, Taiwan) at the Aarhus clinic and with an Omron
M6 Comfort IT (OMRON Corporation, Kyoto, Japan) at
the Copenhagen clinic. Measurements of pulmonary func-
tion forced expiratory volume in one second (FEV1) and
forced vital capacity (FVC) was measured using an
EasyOne® spirometer with EasyOne® disposable
Spirette® tubes (ndd Medical Technologies, Inc.,
Andover, Massachusetts, USA). Testicular size was
measured in privacy at the clinic by the participants them-
selves using a Prader Orchidometer (Bayer AG,
Leverkusen, Germany). This method has previously been
found valid when compared to measurements by an
experienced examiner.36
Assessment of Reproductive Hormones
Nonfasting venous blood samples were collected using
VACUETTE® SAFETY Blood Collection Set + Holder
(Greiner Bio-One GmbH, Kremsmünster, Austria).
Plasma, serum, and whole blood were stored in CryoPure
Tubes (Sarstedt, Nümbrecht, Germany) at −80°C until
analysis of reproductive hormones including hemoglobin
A1c (HbA1c), follitropin (FSH), Insulin-like Growth
Factor I (IGF-1), testosterone, Sex hormone-binding glo-
bulin (SHBG), insulin, lutropin (LH), thyrotropine (TSH),
thyroxine (free T4 and T4), oestradial, and inhibin B.
Analyses currently await funding.
Exposure Biomarkers of Xenobiotic
Chemicals
Besides blood samples urine samples were collected at the
clinics in 150 mL Frascos clear polypropylene containers
with polyethylene leak proof screw caps (DELTALAB S.
L., Barcelona, Spain), both free of phthalates. Samples
were stored at 3–8°C for a maximum of 12 hours before
transfer to polypropylene Microtubes (Sarstedt,
Nümbrecht, Germany) and storage at −80°C.
Figure 2 Overview of the cumulative number of invited and participants in the FEPOS cohort during the study period from March 2017 to December 2019.
Figure 3 Map of the residence of participants in the FEPOS cohort.
Keglberg Hærvig et al Dovepress
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Table 1 Overview of Data Available on the FEPOS Cohort
Category Data
Source
Variables
Prenatal exposure data*
Lifestyle DNBC
telephone
interview at
gestational
weeks 16 and
31
Alcohol
Caffeine
Smoking
Physical activity
Pre-pregnancy body mass index
Stress
Dietary supplements
Employment DNBC
telephone
interview at
gestational
weeks 16 and
31
Work
Workload (only first interview)
Health and
medicine use
DNBC
telephone
interview at
gestational
weeks 16 and
31
Diseases
Over the counter pain medication
Prescribed medication
Nonsteroidal anti-inflammatory
drugs (NSAIDs)
Reproduction DNBC
telephone
interview at
gestational
weeks 16 and
31
Age of onset of puberty
Menstrual cycle characteristics
Birth control
Infertility treatment
Weight gain during pregnancy
Vitamins† Maternal
plasma from
gestational
week 7 or 26
Vitamin D3
Biomarkers of
perfluoroalkyl
acid exposure
(PFFA)†
Maternal
plasma from
gestational
week 7 or 26
Perfluorohexane sulfonic acid
(PFHxS)
Perfluorooctanoic acid (PFOA)
Perfluorooctane sulfonic acid
(PFOS)
Perfluoroheptanoic acid (PFHpA)
Perfluorononanoic acid (PFNA)
Perfluorodecanoic acid (PFDA)
Perfluoroundecanoic acid
(PFUnDA)
Perfluorododecanoic acid
(PFDoDA)
(Continued)
Table 1 (Continued).
Category Data
Source
Variables
Biomarkers of
phthalate
exposure†
Maternal
plasma from
gestational
week 7 or 26
Mono-(2-ethyl-5-oxohexyl)
phthalate (5-oxo-MEHP)
Mono-(2-ethyl-5-hydroxyhexyl)
phthalate (5-OH-MEHP)
Mono-(2-ethyl-5-carboxypentyl)
phthalate (5-cx-MEPP)
Mono-(4-methyl-7-carboxyheptyl)
phthalate (cx-MiNP)
Biomarkers of
additional
xenobiotics†
Maternal
plasma from
gestational
week 7 or 26
Triclosan§
Cotinine§
Acetaminophen (APAP)
Data on sons’ own exposures
Lifestyle FEPOS
questionnaire
Diet
Alcohol
Caffeine
Smoking
Physical activity
Narcotic drugs
Education and
work
FEPOS
questionnaire
Educational level
Work
Health FEPOS
questionnaire
Diseases
Medication
Puberty and
sexual
experience
FEPOS
questionnaire
Puberty
Sexual experience
Physical tests Clinical
examination
Blood pressure
Fat and muscle distribution
Lung function
Testicle size
Semen sample Semen
sample
delivered at
the clinical
examination
Sperm concentration
Semen volume
Total sperm count
Morphology
Motility
DNA fragmentation index (DFI)ǂ
Vitamins† Blood sample
taken at the
clinical
examination
Vitamin D3
(Continued)
Dovepress Keglberg Hærvig et al
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Maternal plasma (100 µL) was retrieved from the
Danish National Biobank (DNB). First trimester plasma
samples were preferred, if these were not available, we
used second or third trimester plasma samples, in that
prioritized order.
Vitamin D, cotinine, and a range of exposure biomarkers
of several xenobiotic chemicals (Table 1) were analyzed in
urine and blood, from both mother and son, using liquid
chromatography-triple quadrupole mass spectrometry
(QTRAP 5500, AB Sciex, Foster City, CA, USA; LC-MS/
MS).37–40 The analysis was performed at the Division of
Occupational and Environmental Medicine at Lund
University, Sweden. Analyses are ongoing – thus far 559
urine samples, 555 blood samples and 533 maternal plasma
samples have been analyzed. The laboratory in Lund is
Table 1 (Continued).
Category Data
Source
Variables
Hormones‡ Blood sample
taken at the
clinical
examination
Hemoglobin A1c (HbA1c)
Follitropin (FSH)
Insulin-like Growth Factor I (IGF-1)
Insulin
Lutropin (LH)
Thyrotropine (TSH)
Thyroxine (T4)
Sexual Hormone Binding Globulin
(SHBG)
Testosterone
Thyroxine (Free T4)
Oestradiol
Inhibin B
Biomarkers of
perfluoroalkyl
acid exposure
(PFFA)†
Blood sample
taken at the
clinical
examination
Perfluorohexane sulfonic acid
(PFHxS)
Perfluorooctane sulfonic acid
(PFOS)
Perfluoroheptanoic acid (PFHpA)
Perfluorooctanoic acid (PFOA)
Perfluorononanoic acid (PFNA)
Perfluorodecanoic acid (PFDA)
Perfluoroundecanoic acid
(PFUnDA)
Perfluorododecanoic acid
(PFDoDA)
Biomarkers of
phthalate
exposure†§
Urine sample
taken at the
clinical
examination
Monoethyl phthalate (MEP)
Monobutyl phthalate (MBP)
Monobenzyl phthalate (MBzP)
Mono-(2-ethylhexyl) phthalate
(MEHP)
Mono-[2-(carboxymethyl)hexyl]
Phthalate (2cx-MEHP)
Mono-(4-methyl-7-hydroxyloctyl)
phthalate (OH-MiNP)
Mono-(4-methyl-7oxo octyl)
phthalate (oxo-MiNP)
Monocarboxyisonoyl Phthalate
(cx-MiDP)
Mono-(propyl-6-hydroxyheptyl)
phthalate (OH-MPHP)
Biomarkers of
phthalate
exposure†§
Blood and
urine taken
at the clinical
examination
Mono-(2-ethyl-5-oxohexyl)
phthalate (5-oxo-MEHP)
Mono-(2-ethyl-5-hydroxyhexyl)
phthalate (5-OH-MEHP)
Mono-(2-ethyl-5-carboxypentyl)
phthalate (5-cx-MEPP)
Mono-(4-methyl-7-carboxyheptyl)
phthalate (cx-MiNP)
(Continued)
Table 1 (Continued).
Category Data
Source
Variables
Biomarkers of
bisphenol
exposure†§
Urine sample
taken at the
clinical
examination
Bisphenol A (BPA)
Bisphenol S (BPS)
Bisphenol F (BPF)
Biomarker of
pesticide
exposure†§
Urine sample
taken at the
clinical
examination
3-Phenoxybenzoic acid (3PBA)
Trichloropyridinol (TCP)
Biomarker of
exposure from
urban pollution
to polycyclic
aromatic
hydrocarbons†§
Urine sample
taken at the
clinical
examination
1-Hydroxypyrene (1-HP)
Biomarker of
smoking†§
Blood and
urine taken
at the clinical
examination
Cotinine
Additional
xenobiotic
chemicals†§
Urine sample
taken at the
clinical
examination
Di-phenylphosphate (DPP)
Additional
xenobiotic
chemicals†§
Blood and
urine taken
at the clinical
examination
Triclosan
Notes: *See DNBC website (https://www.dnbc.dk/) for all data available on
mothers. †Analyses are ongoing. ‡Analyses await funding. §Information on dilution
with density or creatinine is available on all analyses in urine.
Keglberg Hærvig et al Dovepress
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a reference laboratory for bisphenol A (BPA) analysis in
urine and is part of Erlangen Round Robin inter-laboratory
control program for analysis for triclosan, cotinine, trichlor-
opyridinol (TCP), 3-phenoxybencoic acid (3-PBA) and per-
fluoroalkyl acid (PFAA). The laboratory has qualified as
HBM4EU laboratory for the analysis of: BPA, Bisphenol F
(BPF), Bisphenol S (BPS), 1-Hydroxypyren (1-HP)
and Cyclohexane-1,2-dicarboxylate-mono(oxo-isononyl)
ester (oxo-MINCH) and the phthalates; Monobenzyl
(MBzP), Mono-(2-ethylhexyl) (MEHP), Mono-(4-methyl-
7-carboxyheptyl) (cx-MiNP), Mono-(4-methyl-7-hydroxy-
loctyl) (OH-MiNP), Mono-(4-methyl-7oxo octyl) (oxo-
MiNP), Mono (2-ethyl-5-oxohexyl) (5-oxo-MEHP),
Mono(2-ethyl-5-hydroxyhexyl) (5-OH-MEHP), Mono-(2-
ethyl-5-carboxypentyl) (5-cx-MEPP), Perfluoroheptanoic
acid (PFHpA), Perfluorooctanoic acid (PFOA),
Perfluorononanoic acid (PFNA), Perfluorodecanoic acid
(PFDA), Perfluoroundecanoic acid (PFUnDA),
Perfluorododecanoic acid (PFDoDA), Perfluorohexane sul-
fonic acid (PFHxS), and Perfluorooctane sulfonic acid
(PFOS).
Hair Samples
Approximately 150 hair strands (~10–20 mg) were cut
from the vertex posterior as close to the scalp as possible.
The hair strands were stuck on paper with adhesive tape
(Lyreco, Marly, France) with clear indication of the hair
root, and stored in an envelope at room temperature. The
thought was to conduct hair analysis as an indicator of eg
stress,41,42 but no specific studies are planned yet.
Semen Samples
Participants had the option to collect the semen sample at
the clinic or at home. When choosing the latter, detailed
instructions on collection and transportation was sent to
the participant together with a polypropylene sample con-
tainer with a diameter of 79 mm and a height of 22mm,
with polyethylene snap-lid (Nerbe Plus GmbH, Winsen/
Luhe, Germany) for sample collection. This container was
also used to collect the semen sample in the clinic.
Participants were informed that they should be sexually
abstinent 48–72 hours prior to semen collection. All semen
analyses followed the recommendations by the World
Health Organization (WHO) 2010.43 Immediately upon
receipt in the laboratory, the semen volume was measured
by weighing (Scout® SKX222 Portable Precision Balance,
OHAU®, Parsippany, New Jersey, USA) of the sample in
the pre-weighed container. The sample was then placed in
a 37°C HERATherm™ Compact Microbiological
Incubator (Thermo Fisher Scientific, Waltham,
Massachusetts, USA) for liquefaction. After liquefaction
using a TrioMix (Triolab, Brøndby, Denmark), samples
were analyzed manually for sperm concentration, total
sperm count, and motility using a Compudiff 2000–16
Semen Analyzer (Molek AB, Arsta, Sweden). One trained
biomedical laboratory technician affiliated to the clinic in
Copenhagen and another to the clinic in Aarhus performed
all in-house semen analyses. Sperm concentration was
determined on two aliquots of semen samples using a
BLAUBRAND® Improved Neubauer Hemocytometer
(BRAND®, Wertheim, Germany) diluted with NaHCO3
resolution according to concentration. The diluted semen
was transferred to each chamber of the hemocytometer and
put in a humid chamber for 10 minutes. Each chamber was
examined until at least 200 cells had been counted. Sperm
cell motility was determined by counting the proportion of
a) progressive sperm; b) non-progressive sperm; c) immo-
tile sperm, on 200 spermatozoa within each of two fresh
drops of semen, placed on a preheated (37°C), clean glass
slide covered with a cover slip using a Compudiff 2000–16
Semen Analyzer (Molek AB, Arsta, Sweden). Morphology
was analyzed at the Reproductive Medicine Centre,
Skaane University Hospital, in Malmö, Sweden. DNA
fragmentation Index (DFI), measured by flow cytometry
semen chromatin structure assay44 was analyzed at the
Reproductive Medicine Centre, Skaane University
Hospital, in Malmö, Sweden (no results yet).
The FEPOS biomedical laboratory technicians partici-
pated in a follow-up quality control with the Reproductive
Medicine Centre in Malmö where they were originally
trained to perform the semen analyses. In January 2018,
based on five semen samples, the average coefficient of
variation and range for the FEPOS biomedical laboratory
technicians versus the reference laboratory were 18.4%
(10.1–31.4%) versus 17.6% (1.3–28.3%) for sperm con-
centration and 12.7% (2.0–26.0%) versus 38.6% (9.1–
81.6%) for sperm motility. As the Aarhus clinic would
only include participants until June 2018, only the
Copenhagen-based clinic followed the ESHRE External
Quality Assessment scheme (Centre for Andrology,
Karolinska University Hospital, Stockholm, Sweden).
The average Z-scores based on four semen samples at
each test period; winter 2017, spring 2018, and winter
2018, were −0.04 for semen concentration, −0.60 for
motility, and 0.27 for all progressive compared to expert
reference examiners. This was comparable to previous
Dovepress Keglberg Hærvig et al
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studies and well below ± 3, considered acceptable for
semen quality measures.45
Biobank
Additional quantities of biological material were collected
for long-term storage at −80°C in the DNB at Statens
Serum Institut, Copenhagen, Denmark, where all other
samples collected within DNBC are also stored. The
amounts sent to the DNB were three 2 mL MaxxLine
tubes each containing 250 µL semen, three 2 mL
MaxxLine tubes with 1.5 mL urine, four 2 mL MaxxLine
tubes with 600 µL plasma, four 2 mL MaxxLine tubes
containing 600 µL serum, and two 4.5 mL CryoPure tubes
with 3.5 mL EDTA whole blood.
Ethical Approval
This study was conducted in accordance with the
Declaration of Helsinki. The establishment of the FEPOS
cohort was approved by the Scientific Research Ethics
Committee for Copenhagen and Frederiksberg (No.
H-16,015,857) and the Danish Data Protection Agency
(P-2019-503). Recruitment and data collection were also
permitted by the Steering Committee of the DNBC (Ref.
no. 2016–08).
Results
Cohort Characteristics
Selected maternal characteristics are presented in Table 2.
Mean age of the mothers was 30.5 years. Smoking during
first trimester was relatively common (23%) and most
maternal plasma samples were from the first trimester
(92%). Median concentration of mono-(4-methyl-7-car-
boxyheptyl) phthalate measured in blood was 0.3 ng/mL
(10th-90th percentile (p10-p90): 0.2 ng/mL, 0.8 ng/mL)
and median PFOS was 26.3 ng/mL (p10-p90: 17.0 ng/mL,
40.1 ng/mL). Selected characteristics of the sons are pre-
sented in Table 3. Besides more sons from the Aarhus
clinic donating hair samples (90% versus 58% in the
Copenhagen clinic) no big differences between sons from
the Aarhus clinic and the Copenhagen clinic were
observed. Of the 1054 sons who delivered a semen sample
87% chose to do so at the clinics. Azoospermia was
detected in 17 (2%) young men. Median mono-(4-
methyl-7-carboxyheptyl) phthalate measured in urine was
3.6 ng/mL (p10-p90: 1.0 ng/mL, 12.6 ng/mL) and median
PFOS was 4.3 ng/mL (p10-p90: 2.6 ng/mL, 7.2 ng/mL).
Semen parameters are presented in Table 4. The med-
ian total sperm count was 104.9 million for sons from the
Copenhagen clinic compared to 95.9 million among sons
from the Aarhus clinic. The median time from ejaculation
until motility analysis was longer in the Copenhagen clinic
(45 versus 35 minutes). The median values across all other
semen parameters were similar among sons from the
Copenhagen and Aarhus clinics.
Compared to semen parameters of 365 male cohort
members 20–22 years of age in the Testicular Function
Study nested in the Western Australian Pregnancy Cohort
(Raine)46 the median across all semen parameters were a
little lower for FEPOS participants. A slightly lower med-
ian across all semen parameters was also found compared
to those of young Danish men presenting for compulsory
medical examination upon military conscription,47
although the variation in FEPOS was smaller. The most
pronounced differences were for semen volume and total
sperm count which might be due to a slightly longer
ejaculatory abstinence among conscripts than FEPOS par-
ticipant (median 2.5 days versus 2 days). The longer
abstinence time in conscripts can largely be ascribed to
stricter requirements regarding abstinence (participants not
complying were rescheduled) whereas all FEPOS partici-
pants were included even though they did not comply with
abstinence time instructions. Compared to WHO’s lower
reference limits43,48 86% had a semen volume of ≥1.5 mL,
83% had a sperm concentration of ≥15 million/mL, 79%
had a total sperm count of ≥39 million, 95% had ≥32%
motile sperm, and 74% had ≥4% morphologically normal
sperm. As the WHO reference limits were derived by
studies of fertile men who recently became fathers it is
to be expected that less than 95% of an unselected cohort
like FEPOS have semen parameters above the reference
limits.46,48–50
Discussion
To date, only few birth cohorts have detailed maternal
information and biological specimens and a sufficient fol-
low-up period and population size that enables assessment
of prenatal determinants of reproductive parameters in the
offspring.14,51–55 Of these, the Raine Testicular Function
Study46,54 compares best to the FEPOS cohort. With 1058
participants the FEPOS cohort is the largest population-
based male-offspring cohort worldwide with wide-ranging
information on maternal health, lifestyle, socioeconomic
status, occupation, and a maternal blood sample analyzed
for exposure biomarkers of several xenobiotic chemicals
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combined with biological markers of fertility in their sons
collected after puberty. The detailed and prospectively
collected prenatal information allow for comprehensive
confounder control and reduces the risk of information
bias.56 Data collected from the mothers and children at
different timepoints in the children’s lives by the DNBC
and information on environmental exposures collected in
the FEPOS cohort further enables studies on childhood
and adolescence mediators. The possibility for linkage of
the FEPOS cohort to the comprehensive Danish national
health registers further increase the value of the FEPOS
cohort.
The response rate of 19% is in linewith response rates from
previous semen studies56–58 including the semen study among
young Danish conscripts.59 It is lower compared to the Raine
Testicular Function Study of 46% (40% delivered a semen
sample)56 and the Danish study including sons of mothers
from Healthy Habits for Two with a response rate of 49%.23
The lower participation in FEPOS may be explained by the
contact via E-boks which can be challenging for this younger
age group, but the alternatives were too costly and possibly not
more effective. Another reason for the lower participation
could be the demanding recruitment process. To be in accor-
dance with Danish ethical regulations, the recruitment process
involved four steps entirely depending on action from the
youngmen. This included verbal confirmation of participation,
online informed consent, self-administered questionnaire, and
online booking of clinical visit, between the initial invitation
and final participation at the clinics. Future research studies
assessing reproductive health among young men should focus
on how to get hold of participants in a less demanding way.
Differential selection related to exposures, as well as
semen quality has the potential to bias the risk esti-
mates. In studies of fertility, selection bias is often
caused by the higher propensity for participation by
men concerned about their fertility, trying to father
children or previously diagnosed with urogenital disor-
ders or suspected infertility.60 Participants in the FEPOS
cohort were 18–19 years of age and presumably not yet
concerned or aware of their fertility status, which mini-
mizes the risk of self-selection bias. Moreover, a Danish
study found that biomarkers of spermatogenesis, such as
inhibin B level, did not differ between men who chose
to participate in a semen study and men who did not.59
The sons were intentionally not informed about the
specific exposures of interest but only that the focus
was fetal exposure. Therefore, the sons’ participation is
Table 2 Selected Maternal Characteristics of the 1057 Mothers
to the 1058 Included Sons in the FEPOS Cohort*
Characteristics All
N=1057
Age in years, mean [SD] 30.5 [4.2]
Pre-pregnancy body mass index (kg/m2), mean [SD] 22.8 [3.6]
Infertility treated, N (%) 67 (6)
Smokers, N (%) 245 (23)
Cotinine plasma levels (ng/mL)†, median [p10-p90] 0.4 [0.1–50.4]
Number of samples <LOD of 0.2 ng/mL, N (%) 146 (27)
Alcohol consumption (units/week), mean [SD] 0.7 [1.1]
Family occupational status, N (%)
High grade professional 357 (34)
Low grade professional 350 (33)
Skilled worker 203 (19)
Unskilled worker 98 (9)
Student 45 (4)
Unclassified ≤5
Plasma sample available†, N (%)
1st trimester blood sample 489 (92)
2nd trimester blood sample 42 (8)
3rd trimester blood sample ≤5
Biomarkers of perfluoroalkyl acid exposure (PFFA)†, median [p10-p90]
Perfluorooctanoic acid (PFOA) (ng/mL) 4.6 [2.5–7.2]
Number of samples <LOD of 0.02 ng/mL, N (%) 0 (0)
Perfluorooctane sulfonic acid (PFOS) (ng/mL) 26.3 [17.0–
40.1]
Number of samples <LOD of 0.02 ng/mL, N (%) 0 (0)
Biomarkers of phthalate exposure†, median [p10-p90]
Mono-(2-ethyl-5-oxohexyl) phthalate (5-oxo-MEHP)
(ng/mL)
0.1 [<LOD-0.3]
Number of samples <LOD of 0.1 ng/mL, N (%) 271 (51)
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (5-OH-MEHP)
(ng/mL)
0.2 [0.1–0.9]
Number of samples <LOD of 0.05 ng/mL, N (%) 52 (10)
Mono-(2-ethyl-5-carboxypentyl) phthalate (5-cx-MEPP)
(ng/mL)
0.7 [0.4–1.5]
Number of samples <LOD of 0.05 ng/mL, N (%) 0 (0)
Mono-(4-methyl-7-carboxyheptyl) phthalate (cx-MiNP)
(ng/mL)
0.3 [0.2–0.8]
Number of samples <LOD of 0.02 ng/mL, N (%) 0 (0)
Biomarkers of additional xenobiotics†, median [p10-p90]
Triclosan (ng/mL) 1.3 [<LOD-
15.1]
Number of samples <LOD of 0.1 ng/mL, N (%) 107 (20)
Acetaminophen (APAP) (ng/mL) <LOD [<LOD-
1.4]
Number of samples <LOD of 0.5 ng/mL, N (%) 424 (80)
Notes: *One mother had twins. †Analysis is ongoing, so far 532 samples have been
analysed. p10-p90: 10th-90th percentile.
Abbreviation: LOD, Limit of detection.
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Table 3 Selected Characteristics of 1058 Sons Included in the FEPOS Cohort*
Characteristics All Copenhagen Clinic Aarhus Clinic
N=1058 N=830 N=228
Body Mass Index (kg/m2), mean [SD] 22.5 [3.4] 22.5 [3.3] 22.7 [3.6]
Body Composition analysed, N (%) 1055 (100) 829 (100) 226 (99)
Body fat mass (kg), mean [SD] 11.5 [6.7] 11.3 [6.6] 12.3 [6.8]
Muscle mass (kg), mean [SD] 60.8 [7.1] 61.0 [7.1] 60.0 [7.1]
Smoking habits, N (%)
Daily smoking 250 (24) 198 (24) 52 (23)
Occasional/former smoker 296 (28) 241 (29) 55 (24)
Never smoker 508 (480) 389 (47) 119 (52)
Cotinine plasma levels (ng/mL)†§, median [p10-p90] 5.8 [0.3–2951.9] 11.5 [0.4–2540.1] 1.5 [0.3–3124.4]
Number of samples <LOD of 0.3 ng/mL, N (%) 46 (8) 24 (7) 22 (10)
Alcohol drinker, N (%) 984 (93) 769 (93) 215 (94)
Physical activity, N (%)
No physical activity 184 (18) 149 (18) 35 (16)
1 time a week 139 (13) 107 (13) 32 (14)
2 times a week 201 (19) 165 (20) 36 (16)
3 times a week 220 (21) 164 (20) 56 (25)
4 times a week 155 (15) 121 (15) 34 (15)
≥5 times a week 155 (15) 122 (15) 33 (15)
Biospecimens collected, N (%)
Semen 1054 (100) 829 (100) 225 (99)
Blood 1047 (99) 821 (99) 226 (99)
Urine 1042 (99) 819 (99) 223 (98)
Hair 690 (65) 484 (58) 206 (90)
Lung function measured, N (%) 1052 (100) 826 (100) 226 (99)
Forced Expiratory Volume (FVC), mean [SD] 5.6 [0.8] 5.6 [0.8] 5.3 [1.0]
Forced Expired Volume in the first second (FEV1), mean [SD] 4.6 [0.7] 4.7 [0.6] 4.4 [0.9]
Ejaculation at the clinic, N (%) 910 (87) 720 (87) 190 (86)
Spillage of semen sample, N (%) 182 (17) 146 (18) 36 (16)
Season of ejaculation, N (%)
Winter 199 (19) 146 (18) 53 (23)
Spring 205 (19) 142 (17) 63 (28)
Summer 258 (24) 213 (26) 45 (20)
Autumn 396 (37) 329 (40) 67 (29)
Biomarkers of perfluoroalkyl acid exposure (PFFA)†‡, median [p10-p90]
Perfluorooctanoic acid (PFOA)‡ (ng/mL) 1.3 [0.9–2.0] 1.4 [0.9–2.1] 1.3 [0.9–2.0]
Number of samples <LOD of 0.02 ng/mL, N (%) 0 (0) 0 (0) 0 (0)
Perfluorooctane sulfonic acid (PFOS)‡ (ng/mL) 4.3 [2.6–7.2] 4.1 [2.6–6.5] 4.4 [2.8–7.7]
Number of samples <LOD of 0.02 ng/mL, N (%) 0 (0) 0 (0) 0 (0)
(Continued)
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unlikely to depend on exposure status. However, differ-
ential selection together with potential misclassification
of exposure and outcomes should be considered in each
specific hypothesis tested in this population. To mini-
mize the risk of selection bias it is possible to use
selection weights61 in the upcoming FEPOS studies.
Perspectives
The FEPOS cohort provides opportunity to study the “fetal
origins of adult disease hypothesis” related to several sus-
pected exposures.18 Analyses of biological samples for
several xenobiotic chemicals and questionnaire information
from both the mother and son combined with linkage to
nationwide Danish health registers provide countless
research opportunities. The first two publications using the
FEPOS cohort have just been published.62,63 The first study
investigated fetal exposure to paternal smoking and semen
quality in the adult son and found a lower semen concentra-
tion and total sperm count among sons paternally, but not
maternally, exposed to smoking. Indication of a higher risk
of small testicular volume among sons of smoking fathers,
compared to sons of non-smoking fathers were also
Table 3 (Continued).
Characteristics All Copenhagen Clinic Aarhus Clinic
N=1058 N=830 N=228
Biomarkers of pesticide exposure§, median [p10-p90]
Trichloropyridinol (TCP)§ (ng/mL) 1.0 [0.3–3.5] 1.0 [0.4–3.7] 0.9 [0.3–3.2]
Number of samples <LOD of 0.1 ng/mL, N (%) 0 (0) 0 (0) 0 (0)
3-Phenoxybencoic acid (3PBA)§ (ng/mL) 0.3 [0.1–1.1] 0.3 [0.1–1.1] 0.3 [0.1–1.3]
Number of samples <LOD of 0.05 ng/mL, N (%) 31 (6) 20 (6) 11 (5)
Bisphenol A (BPA)†§, median [p10-p90] 1.3 [0.3–5.5] 1.4 [0.4–6.6] 1.2 [0.3–4.7]
Number of samples <LOD of 0.2 ng/mL, N (%) 19 (3) 7 (2) 12 (5)
Biomarkers of phthalate exposure measured in urine†§, median [p10-p90]
Mono-(4-methyl-7-carboxyheptyl) phthalate (cx-MiNP)§ (ng/mL) 3.6 [1.0–12.6] 3.7 [1.0–13.4] 3.5 [1.0–10.5]
Number of samples <LOD of 0.05 ng/mL, N (%) 0 (0) 0 (0) 0 (0)
Mono-(2-ethyl-5-oxohexyl) phthalate (5-oxo-MEHP)§ (ng/mL) 2.6 [0.8–8.1] 2.7 [0.8–8.2] 2.4 [0.7–7.5]
Number of samples <LOD of 0.2 ng/mL, N (%) ≤5 ≤5 0 (0)
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (5-OH-MEHP)§ (ng/mL) 4.5 [1.5–14.3] 4.7 [1.6–15.2] 4.3 [1.3–13.0]
Number of samples <LOD of 0.1 ng/mL, N (%) 0 (0) 0 (0) 0 (0)
Mono-(2-ethyl-5-carboxypentyl) phthalate (5-cx-MEPP)§ (ng/mL) 3.7 [1.1–11.9] 3.9 [1.3–12.4] 3.5 [1.0–10.1]
Number of samples <LOD of 0.07 ng/mL, N (%) 0 (0) 0 (0) 0 (0)
Biomarkers of phthalate exposure measured in blood†‡, median [p10-p90]
Mono-(4-methyl-7-carboxyheptyl) phthalate (cx-MiNP)‡ 0.5 [0.2–1.5] 0.5 [0.2–1.5] 0.5 [0.2–1.5]
Number of samples <LOD of 0.02 ng/mL, N (%) 0 (0) 0 (0) 0 (0)
Mono-(2-ethyl-5-oxohexyl) phthalate (5-oxo-MEHP)‡ <LOD [<LOD-0.1] <LOD [<LOD-0.1] <LOD [<LOD-0.1]
Number of samples <LOD of 0.1 ng/mL, N (%) 532 (96) 314 (95) 218 (96)
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (5-OH-MEHP)‡ <LOD [<LOD-0.1] <LOD [<LOD-0.1] 0.1 [<LOD-0.1]
Number of samples <LOD of 0.05 ng/mL, N (%) 305 (55) 193 (59) 112 (50)
Mono-(2-ethyl-5-carboxypentyl) phthalate (5-cx-MEPP)‡ 0.2 [0.1–0.4] 0.2 [0.1–0.4] 0.2 [0.1–0.3]
Number of samples <LOD of 0.05 ng/mL, N (%) 12 (2) 7 (2) ≤5
Triclosan†‡, median [p10-p90] <LOD [<LOD-0.2] <LOD [<LOD-0.2] <LOD [<LOD-0.2]
Number of samples <LOD of 0.1 ng/mL, N (%) 451 (81) 262 (80) 189 (84)
Notes: *One mother had twins. †Analysis is ongoing, so far 559 urine samples and 555 blood samples have been analysed. ‡Measured in blood. §Measured in urine. p10-p90:
10th-90th percentile.
Abbreviation: LOD, limit of detection.
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observed.62 The second study investigated semen quality
among young men taking protein supplements and found no
association between use of protein supplements and semen
parameters.63
Data Sharing Statement
The FEPOS cohort is managed by researchers from multi-
ple Danish institutions and is overseen by a scientific refer-
ence group consisting of researchers from the DNBC
management group amongst others. The cohort is consid-
ered an open access resource for researchers with projects
that fall within the policy and overall aim of the DNBC
[https://www.dnbc.dk/access-to-dnbc-data]. The scientific
management team reserves the right to prioritize ongoing
projects and encourages external applicants to collaborate
with Danish researchers including principal investigator of
FEPOS, Sandra Søgaard Tøttenborg [sandra.soegaard.toet-
tenborg@regionh.dk]. Further questions can be directed to
the DNBC administrative office [dnbc-research@ssi.dk].
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Table 4 Semen Characteristics of 1054 Sons Who Delivered a Semen Sample in the FEPOS Cohort
Characteristics All Copenhagen Clinic Aarhus Clinic
N=1054 N=829 N=225
Median (5–95 Percentile) Median (5–95 Percentile) Median (5–95 Percentile)
Abstinence time (days) 2.0 (0.5–4.5) 2.0 (0.5–4.5) 2.5 (0.5–4.5)
Semen volume (mL)* 2.7 (1.0–5.4) 2.7 (1.0–5.4) 2.6 (1.0–5.2)
Sperm concentration (million/mL) 38.7 (2.7–138.0) 38.7 (2.8–138.8) 38.6 (2.4–134.8)
Total sperm count (million)* 102.6 (8.1–409.2) 104.9 (7.2–407.2) 95.9 (8.4–417.1)
Motile sperm (%)† 63 (30–83) 64 (31–84) 63 (28–80)
Morphologically normal sperm (%)† 6 (0–15) 6 (0–15) 6 (1–15)
Testicular size (mL) 15 (8–25) 15 (8–25) 15 (8–25)
Minutes until motility analysis 45 (30–90) 45 (35–90) 35 (25–90)
Notes: *182 samples excluded due to spillage. †Motility and morphology not available for 17 sons with azoospermia.
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